CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Quetzal Therapeutics
Immunome, Inc.
Orca Biosystems, Inc.
Kura Oncology, Inc.
Incyte Corporation
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
Merck Sharp & Dohme LLC
Beijing Biotech
Kura Oncology, Inc.
Hangzhou Sumgen Biotech Co., Ltd.
Celgene
Pfizer
AbbVie
Kumquat Biosciences Inc.
Tcelltech Inc.